A new study from the Scripps Translational Science Institute, published in the American Journal of Medicine, shows that iRhythm's Zio patch, a wireless adhesive heart monitor patch, detects more ...

iRhythm Technologies today unveiled initial findings on the post-market and real-world performance of its Zio monitor, building on the devices previous generation of the long-term continuous ...

iRhythm is launching its next generation long-term ambulatory cardiac monitor in the U.S. The new Zio monitor is a prescription-only ECG monitor, which is an integral part of the Zio LTCM service. The ...

Findings published in the American Heart Journal show higher clinical diagnostic yield and lower odds of retesting with Zio long-term continuous monitoring service (LTCM) compared to other LTCM and ...

SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (IRTC) (NASDAQ:IRTC) today announced the commercial launch in Japan of its Zio ® long-term continuous ECG monitoring (LTCM) ...

iRhythm Technologies, Inc. (IRTC) has officially launched its Zio monitor and long-term continuous (LTCM) ECG monitoring service in Austria, the Netherlands, Spain and Switzerland. With CE mark ...

Findings in a younger, commercially insured population build on Medicare-based CAMELOT results, expanding the generalizability of Zio LTCM's clinical impact across patient groups. Latest data showed ...

SAN FRANCISCO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced initial research findings on post-market, real-world performance of Zio® monitor, its ...

The latest update on iRhythm Technologies trims the fair value estimate slightly from about US$221 to roughly US$219, even as long term revenue growth assumptions edge higher from around 17.10% to ...